-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
A Look at Veliparib Plus Chemotherapy for First-Line Treatment of Advanced NSCLC
The strategy likely will not be pursued, however studies of PARP inhibitors plus immune checkpoint inhibitors are already in advanced stages.
-
Study Provides Insights That May Inform Prevention, Management of Mesothelioma
Analysis of worldwide epidemiologic patterns may help governments and medical institutions formulate targeted strategies for addressing mesothelioma.
-
The FDA Explained: An Interview with Dr. Harpreet Singh
During an episode of IASLC’s Lung Cancer Considered podcast, Dr. Singh provided insight into the US agency’s approval process. Here are some highlights.
-
A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?
Interim analysis from ORIENT-31 demonstrates a four-drug regimen may be a reasonable option for patients whose disease has progressed on EGFR TKIs.
-
The OncoKB Precision Oncology Knowledge Base: A Q&A with Dr. Debyani Chakravarty
Finding precision treatments after molecular testing requires a tool for reviewing actionable mutations.
-
Targeting Angiogenesis in Mesothelioma: Insights From MAPS and RAMES
Without validated biomarkers for anti-angiogenesis therapy, VEGF inhibitors are increasingly being investigated.
-
US FDA greenlights nivolumab for use before surgery for NSCLC
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time.
-
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT.
-
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
The UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution.
-
Patient Perspective: Anxiety Follows Abrupt Departure From Clinical Trial
The onboarding required to participate in a clinical trial is extensive. The offboarding, however, can feel like abandonment for some patients.